ASCO 2026 | Multiplex fluorescence atlas informs ADC targets and immune context

This work by Antonio Italiano and colleagues is a work that uses multiplex fluorescence. That means that using a single slide, you can look at six or eight different biomarkers at one time, and they’ve divided their exploration into biomarkers, not only of the ADC targets or antibody-drug conjugate targets, but also of the immune cells and the immune milieu that is probably having an effect. And the key findings are including that the immune cells and the immune context are important. And that’s the reason for the atlas. And also that they looked at some different ADC targets, and they find that the most prevalent ADC target, and hence potentially the most likely to be successful, is a molecule called Trop2, which is already a target of a number of drugs out there. So this is just sort of a discovery or display. They call it an atlas. So it sort of can be used as a reference. In their presentation, they talk about cohorts that are relatively small, between 60 and 80 patients from five different tumor types, which is good, it’s hard to do the work. And so it’s a good amount of work. And it’s a lot of, when you think about 12 or 15 variables on each of 80 patients, it starts to be a lot of data. And that’s what they’ve done. And that sets the foundation for an atlas that they hope other people will be able to contribute to that will ultimately help us decide not only which ADCs to use, but the importance of the immune system on the response to ADCs.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.